Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8790036 | Urologic Oncology: Seminars and Original Investigations | 2018 | 8 Pages |
Abstract
Patients have an incomplete understanding of their own disease prognosis and its therapeutic options. This ultimately influences patient decision-making. Education, income and out-of-pocket costs diminished opinion of CRPC drugs considerably. As such, an EOL premium should be considered in subsets of patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Tarik M.D., M.Sc., Karen M.D., Antonio M.D., Rob M.D., Anthony M. M.D., Ph.D., Girish M.D, Ph.D., Alexandre M.D., Neil M.D., M.P.H.,